Jieqiong Liu - Publications, H-index & Citations

Jieqiong Liu

Sun Yat-sen Memorial Hospital

27H指数

115论文数

2.4K被引数

收录论文 35

发表时间

Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study 新辅助卡瑞利珠单抗联合阿帕替尼作为无化疗策略治疗早期三阴性乳腺癌的疗效、安全性及生物标志物分析：一项II期研究

Breast Cancer Research and Treatment

IF3

2026-08-31

PREAI

Zhenluan Tian; Hengyu Li; Yuxin Deng; Herui Yao; Ying Wang; Liang Jin; Heran Deng; Na Chen; Jieqiong Liu

Multi-responsive nanocomposite hydrogel for synergistic photothermal-chemotherapy to prevent postoperative recurrence and metastasis of uveal melanoma 多功能响应性纳米复合水凝胶用于协同光热-化疗以预防葡萄膜黑色素瘤术后复发和转移

Materials Today Bio

IF10.2

2025-12-03

OAAI

Zhihao Guo; Jiangcheng Tan; Junjie Chen; Jieqiong Liu; Wei Xiao; Xinyuan Huang; Cailing Wei; Ruohua Zhu; Ji-Liang Li

Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial fruroliparib 联合或不联合 apatinib 治疗 HER2 阴性转移性乳腺癌携带胚系 BRCA1/2 突变患者（FABULOUS）：一项多中心、三臂、开放标签、随机、III 期试验的期中分析

The Lancet Oncology

IF0

2025-11-24

PREAI

Huiping Li; Jieqiong Liu; Quchang Ouyang; Shusen Wang; Yaxin Liu; Yuee Teng; Xiaojia Wang; Jing Cheng; Zhongsheng Tong; Tao Sun; Min Yan; Xin Zhou; Fanfan Li; Jianyun Nie; Zhi-Ming Shao; Changsheng Ye; Yongsheng Wang; Xiaohong Wu; Zhihua Li; Yudong Wu

Radiomics signature based on robust features derived from diffusion data for differentiation between benign and malignant solitary pulmonary lesions

CANCER IMAGING

IF3.5

2024-01-22

OAAI

Zhou, Jiaxuan; Wen, Yu; Ding, Ruolin; Liu, Jieqiong; Fang, Hanzhen; Li, Xinchun; Zhao, Kangyan; Wan, Qi

RETRACTION: linc01088 promotes cell proliferation by scaffolding EZH2 and repressing p21 in human non-small cell lung cancer (Retraction of Vol 241, art no 117134, 2020)

LIFE SCIENCES

IF5.1

2023-11-01

OAAI

Liu, Jie-Qiong; Feng, Yu-Hua; Zeng, Shan; Zhong, Mei-Zuo

Fabrication of polyphenol-pumpkin seed protein isolate (PSPI) covalent conjugate microparticles to protect free radical scavenging activity of polyphenol

FOOD BIOSCIENCE

IF5.9

2023-10-01

PREAI

Yang, Chen; Liu, Jieqiong; Han, Yaqian; Wang, Bingyi; Liu, Ziyun; Hu, Haiyue; Guan, Zikuan; Yang, Yutong; Wang, Jianming

Radiomic and clinical data integration using machine learning predict the efficacy of anti-PD-1 antibodies-based combinational treatment in advanced breast cancer: a multicentered study 使用机器学习的影像组学和临床数据整合预测基于anti-PD-1抗体的晚期乳腺癌联合治疗的疗效: 一项多中心研究

JOURNAL FOR IMMUNOTHERAPY OF CANCER

IF10.6

2023-05-22

OAAI

Zhao, Jianli; Sun, Zhixian; Yu, Yunfang; Yuan, Zhongyu; Lin, Ying; Tan, Yujie; Duan, Xiaohui; Wang, Ying; Yao, Herui; Liu, Jieqiong

Impact of Atypical Hyperplasia at Surgical Margins on breast cancer outcomes in patients treated with neoadjuvant chemotherapy

FRONTIERS IN ONCOLOGY

IF3.3

2023-05-19

OAAI

Su, An; Zhang, Jing; Liu, Jieqiong; Yang, Yaping; He, Zhou; Bao, Haoshi; Deng, Heran; Wu, Jiannan

GQ1001: A next generation HER2-targeting ADC that exhibits promising early clinical efficacy with excellent tolerance in a multi-center, Phase Ia study

CANCER RESEARCH

IF16.6

2023-04-14

PREAI

Lemech, Charlotte; Zhou, Chenfei; Zhan, Xianbao; Shi, Yan; Liu, Jieqiong; Piha-Paul, Sarina A.; Richardson, Gary; Qin, Gang; Song, Paul H.; Shi, Lili; Sun, Yajun; Xia, Yi

Radiomic biomarkers to predict the efficacy of anti-PD-1 immunotherapy-based combinational treatment in advanced breast cancer: a multi-center study

CANCER RESEARCH

IF16.6

2023-03-01

PREAI

Liu, Jieqiong; Zhao, Jianli; Sun, Zhixian; Yu, Yunfang; Yuan, Zhongyu; Yao, Herui; Wang, Ying

Single-cell Analysis of KN026 in Combination with KN046 in Treating Patients with Advanced HER2-positive Breast Cancer

CANCER RESEARCH

IF16.6

2023-03-01

PREAI

Liu, Jieqiong; Liao, Jianyou; Tian, Zhenluan; Wang, Jien; Song, Chuangui

Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data

BMC CANCER

IF3.4

2023-01-07

OAAI

Deng, Heran; Wang, Liying; Wang, Na; Zhang, Kejin; Zhao, Yanxia; Qiu, Pengfei; Qi, Xiaowei; Zhang, Danhua; Xu, Fei; Liu, Jieqiong

Predicting Kirsten Rat Sarcoma Virus Gene Mutation Status in Patients With Colorectal Cancer by Radiomics Models Based on Multiphasic CT

FRONTIERS IN ONCOLOGY

IF3.3

2022-06-24

OAAI

Hu, Jianfeng; Xia, Xiaoying; Wang, Peng; Peng, Yu; Liu, Jieqiong; Xie, Xiaobin; Liao, Yuting; Wan, Qi; Li, Xinchun

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

NATURE COMMUNICATIONS

IF15.7

2022-05-31

OAAI

Liu, Jieqiong; Wang, Ying; Tian, Zhenluan; Lin, Ying; Li, Hengyu; Zhu, Zhaowen; Liu, Qiang; Su, Shicheng; Zeng, Yinduo; Jia, Weijuan; Yang, Yaping; Xu, Shengqiang; Yao, Herui; Jiang, Wen; Song, Erwei

Comparison of the Characteristics and Prognosis Between Very Young Women and Older Women With Breast Cancer: A Multi-Institutional Report From China

FRONTIERS IN ONCOLOGY

IF3.3

2022-02-24

OAAI

Yang, Yaping; Wei, Weidong; Jin, Liang; He, Haiyan; Wei, Mengna; Shen, Shiyu; Pi, Hao; Liu, Zhiqin; Li, Hengyu; Liu, Jieqiong

Preliminary safety and efficacy results of KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with KN026 (a HER2-targeted bispecific antibody) in patients with metastatic HER2-positive breast cancer: A phase II trial

CANCER RESEARCH

IF16.6

2022-02-15

PREAI

Liu, Jieqiong; Song, Chuangui; Wang, Xiangcai; Ni, Mingli; Wang, Xujuan; Chen, Lei; Yang, Hongwei; Zhao, Rusen; Xu, Ting; Shen, Lin

Preliminary safety and efficacy results of camrelizumab in combination with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer: A phase II trial

CANCER RESEARCH

IF16.6

2022-02-15

PREAI

Liu, Jieqiong; Tian, Zhenluan; Wang, Ying; Lin, Ying; Li, Hengyu

Clinical practice guideline for breast-conserving surgery in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021

CHINESE MEDICAL JOURNAL

IF7.3

2021-09-20

OAAI

Chen, Kai; Liu, Jie-Qiong; Wu, Wei; Su, Feng-Xi; Zou, Qiang; Song, Er-Wei

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial 依维莫司联合来曲唑与氟尿嘧啶，表柔比星和环磷酰胺治疗ER阳性HER2-negative乳腺癌的新辅助治疗: 一项随机试验

BMC CANCER

IF3.4

2021-07-27

OAAI

Wu, Wei; Chen, Jiewen; Deng, Heran; Jin, Liang; He, Zhanghai; Rao, Nanyan; Nie, Yan; Yao, Yandan; Yang, Yaping; Su, Fengxi; Liu, Jieqiong

Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study eribulin在中国经过大量预处理的转移性乳腺癌患者中的真实疗效: 一项多中心回顾性研究

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

IF4.2

2021-07-09

OAAI

Zhao, Yannan; Xie, Ning; Li, Wei; Chen, Wenyan; Lv, Zheng; Zheng, Yabing; Sun, Tao; Liu, Jieqiong; Zhang, Jian; Hu, Shihui; Wang, Yajun; Gong, Chengcheng; Li, Yi; Xie, Yizhao; Ge, Rui; Xu, Fei; Wang, Biyun

研究方向